



Announcement no. 2/2007

To the Copenhagen Stock Exchange

Copenhagen, January 15th 2007

Financial calendar

Below are the Company's planned dates for financial reporting in 2007:

Year 2006:	March 13 th 2007
Q1 2007:	May 29 th 2007
H1 2007:	August 30 th 2007
Q3 2007:	November 22 nd 2007

The Company's Annual General Meeting is planned for April 23rd 2007.

Yours sincerely,

Curalogic A/S

For additional information, please contact:

Peter Moldt, President and CEO,	Phone +45 33 11 41 01, mobile +45 26 25 04 22
Helle Busck Fensvig, EVP and CFO,	Phone +45 33 11 41 01, mobile +45 20 70 55 37

About Curalogic

Curalogic is a Danish biopharmaceutical company listed on the Copenhagen Stock Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the treatment of allergy. By combining the best of two worlds - the efficacy of immunotherapy combined with the safety and patient convenience of symptomatic treatments – Curalogic aims to develop a novel and user-friendly form of allergy treatment, and make it the preferred type of allergy treatment among patients. Curalogic has a broad and mature pipeline with a product for treatment of ragweed allergy ready for Phase III, products for treatment of grass allergy and cat allergy in Phase II and a product for treatment of house dust mite allergy preparing for clinical trials.